Contributions
Abstract: PB2170
Type: Publication Only
Background
One of the alternative method to mobilize stem cells from bone marrow to peripheral blood is using of vinorelbine with granulocyte colony stimulating factor (G-CSF). The specific features of vinorelbine are absence of hospitalization necessity and predictability of leukocytapheresis’ optimal time. But there is not enough data to conclude whether vinorelbine is safe for haematopoietic stem cells.
Aims
The aim of the study was to determine the colonyforming capacity of haematopoietic stem cells mobilized into peripheral blood with vinirelbine and G-CSF.
Methods
Data of 11 patients with multiple myeloma (MM) and 1 patient with Hodgkin lymphoma (HL) were analyzed. Vinorelbine was injected IV in dose 50-70 mg (35 mg/m2). Daily lenograstim dose was 10 mcg/kg. The number of BFU-E, CFU-GM, CFU-GMME and CFU-Macrophage was studied in 14-days culture: 1x105 cells of leukocytapheresis product were set into Petri dish with MethoCult H 4435 full medium. Control group was consisted of hematopoietic stem cells donors’ data in which G-CSF monotherapy was used for mobilization.
Results
The median patients’ age was 55 (43-64) y. Induction courses for MM treatment included borteszomibe (11 patients), lenalidomide (5 patients) and carfilsomibe (1 patient) in combination with steroids. A patient with HL was treated with ABVD scheme. Leukocytaphereses were started on 6-8 day, herewith in 9/11 (75%) patients on 7 day. The number of gained CD34+ was 1.7-7.8x106/kg (Me 3.3x106/kg). Median number of BFU-E, CFU-GM, CFU-GMME and CFU-Macrophage in patients’ group was 207, 180, 14 and 9 accordingly. The results were not significantly different from control group data: 168, 170, 10 and 12 accordingly; p<0.05.
Conclusion
We conclude that mobilization regimen with vinorelbine in combination with G-CSF does not damage colonyforming capacity of hematopoietic stem cells.
Session topic: 22. Stem cell transplantation - Clinical
Abstract: PB2170
Type: Publication Only
Background
One of the alternative method to mobilize stem cells from bone marrow to peripheral blood is using of vinorelbine with granulocyte colony stimulating factor (G-CSF). The specific features of vinorelbine are absence of hospitalization necessity and predictability of leukocytapheresis’ optimal time. But there is not enough data to conclude whether vinorelbine is safe for haematopoietic stem cells.
Aims
The aim of the study was to determine the colonyforming capacity of haematopoietic stem cells mobilized into peripheral blood with vinirelbine and G-CSF.
Methods
Data of 11 patients with multiple myeloma (MM) and 1 patient with Hodgkin lymphoma (HL) were analyzed. Vinorelbine was injected IV in dose 50-70 mg (35 mg/m2). Daily lenograstim dose was 10 mcg/kg. The number of BFU-E, CFU-GM, CFU-GMME and CFU-Macrophage was studied in 14-days culture: 1x105 cells of leukocytapheresis product were set into Petri dish with MethoCult H 4435 full medium. Control group was consisted of hematopoietic stem cells donors’ data in which G-CSF monotherapy was used for mobilization.
Results
The median patients’ age was 55 (43-64) y. Induction courses for MM treatment included borteszomibe (11 patients), lenalidomide (5 patients) and carfilsomibe (1 patient) in combination with steroids. A patient with HL was treated with ABVD scheme. Leukocytaphereses were started on 6-8 day, herewith in 9/11 (75%) patients on 7 day. The number of gained CD34+ was 1.7-7.8x106/kg (Me 3.3x106/kg). Median number of BFU-E, CFU-GM, CFU-GMME and CFU-Macrophage in patients’ group was 207, 180, 14 and 9 accordingly. The results were not significantly different from control group data: 168, 170, 10 and 12 accordingly; p<0.05.
Conclusion
We conclude that mobilization regimen with vinorelbine in combination with G-CSF does not damage colonyforming capacity of hematopoietic stem cells.
Session topic: 22. Stem cell transplantation - Clinical